Jeffrey Williams Joins emerGen as Vice President, Corporate Development and Strategy

Apr 19, 2001, 01:00 ET from emerGen, Inc.

    SALT LAKE CITY, April 19 /PRNewswire/ -- emerGen, Inc. announced today
 that Jeffrey Williams joined the company as Vice President, Corporate
 Development and Strategy.  He will lead the company's rapidly expanding
 business development activities and strategic direction.
     Mr. Williams joins emerGen from Anesta Corp. where he was Vice President
 of the Office of Development.  He was responsible for all licensing
 activities, intellectual property, program management, information systems and
 corporate strategy, including the direction of the company's recent merger
 with Cephalon, Inc.  Prior to joining Anesta, Mr. Williams worked for Vertex
 Pharmaceuticals in program management and business development and for Phase V
 Technologies, a consulting firm specializing in pharmacoeconomic and quality
 of life studies.  He obtained his Masters of Science from the Sloan School of
 Management at the Massachusetts Institute of Technology.
     President and chief executive officer, Keith Wilson, expressed his
 pleasure at strengthening the company's senior management team with the
 addition of Jeff Williams.  "Jeff's extensive experience across a wide range
 of business, planning, and operations at other fast growing biotechnology
 companies is of particular relevance to our business and development
 technologies.  Jeff will be leveraging our technology through various
 alliances and partnerships to further accelerate our growth in the exciting
 field of women's health."
     Mr. Williams is enthusiastic about emerGen's prospects for growing into
 the premier women's health company.  "The extensive outcomes databases that
 emerGen has developed will revolutionize the research and development of
 diagnostics and therapeutics for the largely underserved women's health
 market."
     EmerGen is a leading biopharmaceutical company focused on the discovery of
 novel therapeutics and diagnostics to address significant unmet medical needs
 in the areas of women's health and reproductive biology.  Through its own
 collections and collections licensed from the University of Utah, emerGen has
 amassed the most comprehensive databases and sample collections in the world
 for conducting genetic, genomic, and proteomic research in the fields of
 women's health and reproductive biology.  The company has more than
 250,000 DNA and tissue samples matched with clinical data, patient histories
 and genealogical data.  These resources, together with an extensive clinical
 investigator network and unmatched expertise in developmental and reproductive
 biology permits ready segregation of genetic from environmental factors and
 the rapid identification of key genes, proteins, and pathways involved in
 women's health.  EmerGen has four product development programs in the areas of
 polycystic ovary syndrome, preterm labor, infertility and gestational
 diabetes.
     The company is based in the University of Utah Research Park in Salt Lake
 City, Utah, USA.
     Further information about emerGen, Inc. can be found at:
 http://www.emergenlabs.com
 
 

SOURCE emerGen, Inc.
    SALT LAKE CITY, April 19 /PRNewswire/ -- emerGen, Inc. announced today
 that Jeffrey Williams joined the company as Vice President, Corporate
 Development and Strategy.  He will lead the company's rapidly expanding
 business development activities and strategic direction.
     Mr. Williams joins emerGen from Anesta Corp. where he was Vice President
 of the Office of Development.  He was responsible for all licensing
 activities, intellectual property, program management, information systems and
 corporate strategy, including the direction of the company's recent merger
 with Cephalon, Inc.  Prior to joining Anesta, Mr. Williams worked for Vertex
 Pharmaceuticals in program management and business development and for Phase V
 Technologies, a consulting firm specializing in pharmacoeconomic and quality
 of life studies.  He obtained his Masters of Science from the Sloan School of
 Management at the Massachusetts Institute of Technology.
     President and chief executive officer, Keith Wilson, expressed his
 pleasure at strengthening the company's senior management team with the
 addition of Jeff Williams.  "Jeff's extensive experience across a wide range
 of business, planning, and operations at other fast growing biotechnology
 companies is of particular relevance to our business and development
 technologies.  Jeff will be leveraging our technology through various
 alliances and partnerships to further accelerate our growth in the exciting
 field of women's health."
     Mr. Williams is enthusiastic about emerGen's prospects for growing into
 the premier women's health company.  "The extensive outcomes databases that
 emerGen has developed will revolutionize the research and development of
 diagnostics and therapeutics for the largely underserved women's health
 market."
     EmerGen is a leading biopharmaceutical company focused on the discovery of
 novel therapeutics and diagnostics to address significant unmet medical needs
 in the areas of women's health and reproductive biology.  Through its own
 collections and collections licensed from the University of Utah, emerGen has
 amassed the most comprehensive databases and sample collections in the world
 for conducting genetic, genomic, and proteomic research in the fields of
 women's health and reproductive biology.  The company has more than
 250,000 DNA and tissue samples matched with clinical data, patient histories
 and genealogical data.  These resources, together with an extensive clinical
 investigator network and unmatched expertise in developmental and reproductive
 biology permits ready segregation of genetic from environmental factors and
 the rapid identification of key genes, proteins, and pathways involved in
 women's health.  EmerGen has four product development programs in the areas of
 polycystic ovary syndrome, preterm labor, infertility and gestational
 diabetes.
     The company is based in the University of Utah Research Park in Salt Lake
 City, Utah, USA.
     Further information about emerGen, Inc. can be found at:
 http://www.emergenlabs.com
 
 SOURCE  emerGen, Inc.